Satellos Bioscience Inc. (MSLE)
About Satellos Bioscience Inc.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $117.1M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $117.1M
- Shares outstanding
- 12.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 18, 2021
Satellos Bioscience Inc. (MSLE) Stock Price
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Satellos Bioscience Inc..
Write a review
News about Satellos Bioscience Inc.
News & sentiment via Polygon.io
Satellos Bioscience Inc.: frequently asked questions
Is Satellos Bioscience Inc. an American company?
Satellos Bioscience Inc. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Satellos Bioscience Inc. publicly traded?
Yes — Satellos Bioscience Inc. is a publicly traded company. Its stock trades under the ticker symbol MSLE on the NASDAQ.
What does Satellos Bioscience Inc. do?
Satellos Bioscience Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
